Bayer stops drug trial with haemophilia drug BAY 86-6150

FRANKFURT Fri May 3, 2013 10:17am EDT

Related Topics

FRANKFURT May 3 (Reuters) - Bayer said its HealthCare division stopped a Phase II/III study testing its experimental treatment BAY 86-6150 on certain haemophilia A and B patients due to safety concerns.

"The hope that BAY 86-6150 might help patients with inhibitors to achieve better control of their disease could not be fulfilled due to the detection of a neutralizing antibody in the trial," the company said on Friday. (Reporting by Ludwig Burger)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.